DJIA 18,030.21 6.04 0.03%
NASDAQ 4,773.47 0.00 0.00%
S&P 500 2,081.88 -0.29 -0.01%
market minute promo

Ophthotec (NASDAQ: OPHT)

44.93 1.06 (2.42%)

Quote as of


company name or ticker

Recent Quotes

OPHT $44.93 2.42%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $44.15
Previous Close $43.87
Daily Range $44.15 - $45.65
52-Week Range $28.60 - $50.00
Market Cap $1.5B
P/E Ratio 3.00
Dividend (Yield) $0.00 (0.0%)
Volume 98,404
Average Daily Volume 314,397
Current FY EPS -$2.32

Sector

Industry

Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary

Why Novartis and Regeneron Care About This Tiny Biotech Stock

Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.

AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog

UPDATE: Stifel Reiterates On Ophthotech Corp Following 3Q14 Report

Ophthotech's (OPHT) CEO Dr. David Guyer on Q3 2014 Results - Earnings Call Transcript

Pre-Market Earnings Report for November 11, 2014 : DHI, ACM, CST, NGL, OPHT, INSY, QIWI, PETX, GTT,

Pre-Market Earnings Report for November 11, 2014 : DHI, ACM, CST, NGL, OPHT, INSY, QIWI, PETX, GTT, CPTA, CLUB, SEMFF

3 Small-Cap Biotech Stocks to Buy if the Market Crashes

Falling markets may be creating an opportunity to pick up these three biotechnology companies at discount prices.

Ohr Pharamceuticals: Stay On The Sidelines

Sector Update: Health-Care Shares Mixed in Pre-Market Trade

Sector Update: Health Care

Ophthotech's (OPHT) CEO David Guyer on Q2 2014 Results - Earnings Call Transcript

See More OPHT News...